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The Genetic and environmental risk Factors of Alzheimer’s disease
Alzheimer is one of the most common neurodegenerative dis-
ease generally found in the form of dementia in old age popu-
lation. Advanced age is still considered as most influencing risk 
factors for this disease.  WHO reported that dementia is the sev-
enth leading cause of death in 2018 and affecting about fifty mil-
lion people worldwide. Aging led to impair protein metabolism in 
the Alzheimer’s disease. A number of molecular events has been 
implicated behind this disease. As AD is a chronic neurodegen-
erative disease and etiology is still unclear, familial AD accounts 
only 5% of the disease. Then it is important to know about some 
other hidden risk factors that may play crucial role in the onset of 
the disease. Thus, this paper focused on the role of genetics, dif-
ferent environmental, oxidative stress factors and its association 
with the pathogenesis of Alzheimer’s disease.
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Introduction: 
Alzheimer affects over 34 million people 
worldwide. AD is the most common 
neurodegenerative disease found in the form of 
dementia in the elderly population and accounts 
to 60–70% of cases. It is a progressive and 
irreversible loss of memory and cognition 
impairment. [1] Advanced age is most 
vulnerable to this disease. Disease onset is 
classified into two types: early-onset (<60 years 
of age) EOAD and late-onset LOAD (> years of 
age). A very less percentage of the disease is 
genetically mutated is called familiar onset of 
Alzheimer’s disease (FAD), and it is usually 
early-onset. When no family history is present, 
the form is called sporadic. [2] Genes that are 
responsible for the EOAD are amyloid 
precursor protein (APP), presenilin 1 (PSEN1), 
and presenilin 2 (PSEN2).  After the action of 
various secretase enzymes on APP produces 
Aβ is a natural product that helps in neuronal 
growth and repair.  Altered production of 
amyloid beta (Abeta) both Abeta 40 and Abeta 
42) is found due to mutation in these genes.  
Abeta is supposed to lead apoptosis of the 
neurons results in dementia. [3-6] One of the 
important gene is considered a genetic risk 
factor for LOAD and that has been validated 
from different population based studies is 
APOE located on chromosome 19. [7] The 
pathological hallmark of AD is the presence 
extracellular deposits of protein called amyloid 
beta or senile plaques and intracellular 
neurofibrillary tangles (NFT). [8]   Now it is 
considered that environmental and genetic risk 
factors may play a positive role in disease 
onset. No specific treatment is available.  
Pathogenesis of Alzheimer disease: 
The action of proteases, the α-, β-, and γ 
secretases on larger protein, i.e. amyloid 
precursor protein leads to the production of 
amyloid beta in senile plaque. [9] The γ- 
secretase may be responsible for production of 
one particular β- amyloid peptide Aβ42 that is 
42 amino acids in length that has pathogenetic 
importance, because it is form insoluble toxic 
fibrils and accumulates in the senile plaques 
isolated from the brains of Alzheimer’s patients. 
[10,11] Production of β-amyloid in the brain is 
normal process, but excess production and 
impaired clearance by the central nervous 
system in AD patients, further accelerating the 
accumulation of plaques. [12] Genetic role in 
Alzheimer’s disease: 
More than 90% of patients with AD are late 
onset of disease (LOAD) have no family history 
and sporadic in nature. [13] No causative gene 
has been identified yet, but twin study 
supported the role of a genetic component in 
LOAD. Moreover, the only one gene that has 
been consistently found to be associated with 
sporadic LOAD in multiple genetic studies, is 
the apolipoprotein E (APOE) gene. [14-18] 
ApoE gene produces the apolipoprotein in the 
brain where it is synthesized and secreted 
primarily by astrocytes in high-density  
lipoprotein  (HDL) -like  particle. [19] A primary 
function of ApoE is the transportation of 
cholesterol to neurons. That is essential for 
axonal growth, synaptic formation, memory 
formation and neuronal repair. [20, 21] The 
synaptic remodeling impairment and synaptic 
loss occur due to the decreased level of ApoE 
in the cortex and hippocampus region of the 
brain. [22, 23] Three common polymorphic 
allele of ApoE protein is found as APOE2, 
APOE3 and APOE4.  The  APOE4   form of the 
gene is supposed to be the reliable genetic 
biomarker for the  late onset of Alzheimer’s 
disease (LOAD),  it has possibly increased the 
level of risk three times in heterozygous 
individuals and by twelve times in  homozygous  
individuals. [24] The least frequent allele 
APOE2 is found only in 5–10% of individuals 
are considered to have a more protective effect 
against the AD onset, while the APOE3 gene 
has been shown intermediate risk possibilities 
in about 70- 80 % of the individuals. [25, 26] So 
many studies have revealed that in mild 
cognitive impairment (MCI) prevalence of E4 
allele is higher than in control individuals. [27] 
Recent evidences are suggesting the 
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overwhelming role of the microglial molecular 
network in the AD pathophysiology. [28] 
Microglia cells have protective function against 
the accumulation of Aβ and TREM 2 gene 
mutation (R62H, R47H, and D87N) in the brain 
are the important risk factor of AD. Moreover, 
cultured cells of TREM2 mutation show 
expression in disrupting translocation of cell 
membrane and impaired ligand binding 
property. [29- 31] 
 
 
 
Figure 1. This diagram depicting the action of protease enzymes on APP and production of 
amyloid beta that finally leading to Alzheimer’s disease. 
 
Environmental role in Alzheimer’s disease: 
Previous studies are providing the evidence 
that environmental factors may play crucial role 
in the pathogenesis Alzheimer’s disease as the 
prevalence and incidence of late onset of 
disease, indicating towards the age is the most 
common known risk factor. The prevalence of 
AD increases significantly with age and 
incidence increases from 2.8 per 1000 person 
years for people between 65 to 69 years and 
56.1 per 1000 person years for people who are 
older than 90 years. [28] It is well established 
that several essential transition metals, such as 
zinc, iron, copper, selenium, cobalt and 
manganese play vital role in the control of 
different metabolic and signaling pathways. 
Patients have been found with altered metal 
homeostasis in the brain and plasma/ serum, 
ROS 
Metal dishomeostasis 
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level compared with age-matched controls, AD 
patients show elevated  zinc  and  copper  in  
cerebro-spinal  fluid  (CSF). [29] Senile plaques 
and NFTs were found to enriched with this 
metal. [30] Some metals have been found to 
facilitate Aβ aggregation.  In presence of zinc 
and copper Aβ tends to form fibrils, oligomers 
respectively. [31] In AD patients, the presence 
of transition metals within amyloid plaques 
indicates the possible interaction with abeta. 
[32-34] 
Oxidative stress: 
Oxidative stress is state that leads the 
overproduction of free radicals. In AD oxidative 
stress is found as a result of amyloid beta 
misfolding. [35] In AD amyloid beta peptide 
shows a direct source of free radical production 
in which methionine, at the position of 35, is 
supposed to be responsible. [36] Abeta  directly 
disrupts mitochondrial function due to less 
energy metabolism neuronal death occur. [37] 
Reactive oxygen species (ROS) may play a 
role in many chronic diseases and 
neurodegenerative diseases. [38-40] 
Mitochondrial dysfunction involves changes in 
mitochondrial enzymes, structure, impaired 
mitochondrial fission and fusion was found 
altered in AD. [41]  
The relation between oxidative stress and tau 
pathology has been less studied. The cells 
overexpressing tau protein had increased 
susceptibility against oxidative stress [42] 
Moreover, oxidative stress is able to damage 
DNA strand and large deletions that can 
change different enzymatic and mitogenic 
pathways.  DNA methylation may influence by 
oxidative stress, which helps in the regulation of 
gene expression. [43] Interestingly, oxidative 
stress has been shown to decrease 
neurogenesis in the adult brain, thus limiting its 
neurodegenerative capacity. [44,45] One study 
found a direct relation between oxidative stress 
and brain cognition severity. [46] Recent 
studies are showing that altered metal 
homeostasis may play role in oxidative stress. 
Evidence supporting that metal dependent 
enzymatic process of the brain is disrupted in 
AD. [47, 48] Aging process is itself an important 
reason to increase oxidative stress. [49] 
Conclusion: 
As the AD is multifactorial in nature due to this 
specific biomarker is not available currently. 
[50] Progressive brain atrophy and cognition 
impairment lead the patient to face trouble in 
performing daily routine activities. [51] 
Increased apoptosis have been seen in AD 
person caused by oxidative stress results in 
lipid oxidation, protein oxidation and damage of 
the DNA strand. [52] Metal ions may also 
contribute to AD by accelerating protein 
aggregation. Copper, zinc and iron are found in 
high micromolar concentrations in amyloid 
plaques because Aβ is able to bind these 
metals with different affinities. [53,56] There are 
growing evidence that are suggesting a role of 
heavy metals in AD. Genetic mutations 
accounts only about 5% of the disease, 
remaining other factors may play hidden 
positive role in the disease onset. 
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